Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 4.1%

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) dropped 4.1% during trading on Monday . The company traded as low as $24.75 and last traded at $24.75. Approximately 33,807 shares changed hands during trading, a decline of 77% from the average daily volume of 144,789 shares. The stock had previously closed at $25.80.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Stifel Nicolaus initiated coverage on shares of Dianthus Therapeutics in a research report on Thursday, February 15th. They set a “buy” rating and a $44.00 price target for the company. Jefferies Financial Group upped their target price on shares of Dianthus Therapeutics from $22.00 to $39.00 and gave the stock a “buy” rating in a research note on Friday, March 22nd. Wedbush raised their price target on shares of Dianthus Therapeutics from $24.00 to $33.00 and gave the company an “outperform” rating in a research report on Friday, March 22nd. Finally, Raymond James upped their price objective on Dianthus Therapeutics from $34.00 to $51.00 and gave the company an “outperform” rating in a research report on Thursday, April 18th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $42.40.

Dianthus Therapeutics Stock Performance

The business’s 50 day simple moving average is $25.56 and its two-hundred day simple moving average is $18.02.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Thursday, March 21st. The company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($1.11) by $0.40. The business had revenue of $0.46 million during the quarter, compared to the consensus estimate of $0.73 million. As a group, equities research analysts predict that Dianthus Therapeutics, Inc. will post -1.92 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. FMR LLC purchased a new position in Dianthus Therapeutics during the third quarter worth $28,961,000. Avidity Partners Management LP purchased a new position in shares of Dianthus Therapeutics during the third quarter valued at approximately $16,644,000. Atlas Venture Life Science Advisors LLC purchased a new stake in shares of Dianthus Therapeutics in the third quarter worth approximately $3,240,000. Vestal Point Capital LP purchased a new position in Dianthus Therapeutics during the 4th quarter valued at $1,404,000. Finally, Octagon Capital Advisors LP grew its position in Dianthus Therapeutics by 15.4% in the 4th quarter. Octagon Capital Advisors LP now owns 554,000 shares of the company’s stock valued at $5,762,000 after acquiring an additional 74,000 shares during the last quarter. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.